Reitox national focal points
The Reitox national focal points are made up of the 27 EU Member States, plus Norway and Turkey. These countries directly contribute to the EMCDDA’s core task of collecting and reporting consistent, harmonised and standardised information on the drug phenomenon across Europe.
Candidates and potential candidates to the EU
The EMCDDA cooperates with candidates and potential candidates to the EU. The current enlargement agenda of the EU covers the partners of the Western Balkans (Albania, Bosnia and Herzegovina, Kosovo*, Montenegro, North Macedonia and Serbia) and Turkey**.
*Kosovo: this designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.
**Turkey is not included in this section as it is a member of the EMCDDA Management Board and part of the EMCDDA's Reitox network.
European Neighbourhood Policy area
The EMCDDA has been cooperating with countries of the European Neighbourhood Policy (ENP)* area for many years.
*ENP: The European Neighbourhood Policy (ENP) governs the EU's relations with 16 of the EU's closest Eastern and Southern Neighbours. The EMCDDA is currently managing the EU4Monitoring Drugs (EU4MD) project which will run from 2019 until the end of 2021 and will involve ENP countries. Syria and Egypt are not participating in the EU4MD project.
**Palestine: This designation shall not be construed as recognition of a State of Palestine and is without prejudice to the individual positions of the Member States on this issue.
***Due to Russia's invasion of Ukraine, and in line with the EU position, ongoing and planned bilateral engagement between the EMCDDA and representatives of Russia and Belarus has been suspended with immediate effect.
Other third countries
In addition to the countries above, the EMCDDA also has cooperation with other non-EU countries.